News & Resources.

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration

Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy, announced the selection of its Nanoprimer technology by the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization, based on its potential to significantly impact treatments in multiple disease indications, including cancer. […]

Continue Reading...

NANOBIOTIX ANNOUNCES THE LAUNCH OF CURADIGM: A NEW NANOTECHNOLOGY PLATFORM FOR HEALTHCARE

NANOBIOTIX ANNOUNCES THE LAUNCH OF CURADIGM: A NEW NANOTECHNOLOGY PLATFORM FOR HEALTHCARE

After achieving the milestone of our first European market approval for Nanobiotix’s lead oncology product candidate, NBTXR3, our business continues to build momentum. We are thrilled to announce the launch of our subsidiary, Curadigm—another disruptive technology platform we have built as a result of pioneering nanomedicine for more than 15 years. While Nanobiotix remains focused on continued development of NBTXR3, we are pleased to open new growth pathways for our business and shareholders. […]

Continue Reading...